Founded in 1929 as a family business, Ipsen develops and brings pharmaceutical medicines to patients with significant unmet medical needs. The global biopharmaceutical company has more than 5,000 employees and concentrates its research and portfolio on oncology, rare disease and neuroscience, with products registered in 88 countries. Its history includes early manufacturing in France and a long-standing focus on translating scientific discovery into scalable, patient-ready treatments.